Optimizing Multidisciplinary Care of Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus

被引:8
|
作者
Kelepouris, Ellie [1 ]
St. Peter, Wendy [2 ,3 ]
Neumiller, Joshua J. [4 ]
Wright, Eugene E. [5 ]
机构
[1] Univ Penn, Div Renal Electrolyte & Hypertens, Philadelphia, PA 19104 USA
[2] Univ Minnesota, Minneapolis, MN USA
[3] Hennepin Healthcare Res Inst, Minneapolis, MN USA
[4] Washington State Univ, Spokane, WA USA
[5] Charlotte Area Hlth Educ Ctr, Charlotte, NC USA
关键词
Chronic kidney disease; Type 2 diabetes mellitus; Multidisciplinary care; Multidisciplinary team; Care optimization; Prevention; CARDIOVASCULAR OUTCOMES; PHARMACIST INTERVENTION; MEDICATION ADHERENCE; THERAPY MANAGEMENT; NEPHROPATHY; NEPHROLOGY; MORTALITY; CKD; HOSPITALIZATION; FINERENONE;
D O I
10.1007/s13300-023-01416-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes is the leading cause of chronic kidney disease (CKD), a condition associated with significant morbidity and mortality. As these patients have a high risk of developing cardiovascular disease and end-stage kidney disease, there is a need for early detection and early initiation of appropriate therapeutic interventions that slow disease progression and prevent adverse outcomes. Due to the complex nature of diabetes and CKD management, a holistic, patient-centered, collaborative care approach delivered by a coordinated multidisciplinary team (ideally including a clinical pharmacist as part of a comprehensive medication management program) is needed. In this review, we discuss the barriers to effective care, the current multidisciplinary approach used for CKD prevention and treatment, and the potential ways that the multidisciplinary management of CKD associated with type 2 diabetes mellitus can be refined to improve patient outcomes.
引用
收藏
页码:1111 / 1136
页数:26
相关论文
共 50 条
  • [41] Chronic kidney disease in type 2 diabetes mellitus patients: Comparison of KDIGO and KDOQI guidelines
    Ephraim, Richard K. D.
    Mantey, Richard
    Atombo, Stephen
    Sakyi, Samuel A.
    Fondjo, Linda A.
    Tashie, Worlanyo
    Agbodzakey, Hope
    Botchway, Felix A.
    Amankwaa, Bright
    ALEXANDRIA JOURNAL OF MEDICINE, 2018, 54 (04) : 445 - 449
  • [42] Survival benefit of nephrologic care in patients with diabetes mellitus and chronic kidney disease
    Tseng, Chin-Lin
    Kern, Elizabeth F. O.
    Miller, Donald R.
    Tiwari, Anjali
    Maney, Miriam
    Rajan, Mangala
    Pogach, Leonard
    ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (01) : 55 - 62
  • [43] The Kidney Effects of the SGLT2 Inhibitors on the Japanese Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease
    Kobayashi, Kazuo
    Toyoda, Masao
    Hatori, Nobuo
    Sakai, Hiroyuki
    Furuki, Takayuki
    Tamura, Kouichi
    Miyakawa, Masaaki
    DIABETES, 2019, 68
  • [44] Optimizing Utilization of SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease in a VA Primary Care Clinic: An Interdisciplinary Quality Improvement Project
    de la Serna, Solanus
    Prathivadhi-Bhayankaram, Sruti
    Anderson, Rachel
    Zandvakili, Arya
    Day, Jonathan
    Hines, Mackenzie
    Vather-Wu, Naomi
    Salomone, Joseph
    Zeithamel, Marcia
    Meyer, Meaghan
    Brettell, Leslie
    Johnson, Krista
    Zetumer, Samuel
    Hupp, Derek
    AMERICAN JOURNAL OF MEDICAL QUALITY, 2024, 39 (04) : 199 - 200
  • [45] Management of diabetes mellitus in patients with chronic kidney disease
    Allison J. Hahr
    Mark E. Molitch
    Clinical Diabetes and Endocrinology, 1 (1):
  • [46] THE IMPACT OF CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES MELLITUS ON SOCIAL COST IN CHRONIC KIDNEY DISEASE PATIENTS IN ITALY
    Bellelli, S.
    Turchetti, G.
    VALUE IN HEALTH, 2014, 17 (07) : A468 - A468
  • [47] Diabetes mellitus and anaemia in patients with chronic kidney disease
    Lejnieks, A.
    Kuzema, V.
    Petersons, A.
    DIABETOLOGIA, 2008, 51 : S485 - S485
  • [48] Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
    Wanner, Christoph
    Lachin, John M.
    Inzucchi, Silvio E.
    Fitchett, David
    Mattheus, Michaela
    George, Jyothis
    Woerle, Hans J.
    Broedl, Uli C.
    von Eynatten, Maximilian
    Zinman, Bernard
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    CIRCULATION, 2018, 137 (02) : 119 - 129
  • [49] Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
    Merlin C. Thomas
    Mark E. Cooper
    Paul Zimmet
    Nature Reviews Nephrology, 2016, 12 : 73 - 81
  • [50] Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
    Thomas, Merlin C.
    Cooper, Mark E.
    Zimmet, Paul
    NATURE REVIEWS NEPHROLOGY, 2016, 12 (02) : 73 - 81